Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.

about

Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.

Item

http://www.wikidata.org/entity/Q38805440

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical manifestations and pa ...... status and future directions.

@en

type

Item

label

Clinical manifestations and pa ...... status and future directions.

@en

prefLabel

Clinical manifestations and pa ...... status and future directions.

@en

P1476

Clinical manifestations and pa ...... status and future directions.

@en

P2093

Belen Rubio-Gonzalez

http://www.w3.org/2001/XMLSchema#string

Christiane Querfeld

http://www.w3.org/2001/XMLSchema#string

Jasmine Zain

http://www.w3.org/2001/XMLSchema#string

Steven T Rosen

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma

Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.

Durable loss of a malignant T-cell clone in a stage IV cutaneous T-cell lymphoma patient treated with high-dose interferon and photopheresis.

Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors

Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.

P304

16-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.14402

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

176

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27782301

http://www.w3.org/2001/XMLSchema#string